Japan Diabetes Drugs Market Expected to Reach USD 5.9 Billion by 2033 - IMARC Group

January 24, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

Japan Diabetes Drugs Market Statistics, Outlook and Regional Analysis 2025-2033

The Japan diabetes drugs market size was valued at USD 4.4 Billion in 2024, and it is expected to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 3.5% from 2025 to 2033.

Japan Diabetes Drugs Market

To get more information on this market, Request Sample

In Japan, the diabetes drugs industry is developing, driven by new therapeutic applications and rising rates of obesity and diabetes. Along with this, the geriatric populations and sedentary lifestyles have catalyzed the need for effective therapies targeting type 2 diabetes and related metabolic disorders. Correspondingly, companies are utilizing advances in pharmacology and molecular biology to develop next-generation diabetes therapies that deliver satisfactory results and fulfill unmet medical requirements. In line with these trends, Kumamoto University introduced HPH-15 in December 2024, a diabetes drug indicating premium efficacy compared to metformin. This innovation offers significant potential for diabetes and obesity management, addressing two major health challenges in Japan.

Correspondingly, in August 2024, Sumitomo Pharma and Poxel announced positive outcomes from the post-marketing analysis of TWYMEEG for type 2 diabetes patients with renal impairment. The analysis revealed that TWYMEEG is safe and well-tolerated, potentially leading to guideline updates for patients. Concurrently, pharmaceutical companies' strategic alliances and cooperation are also influencing the industry. This makes advanced therapies widely available. For example, Mitsubishi Tanabe Pharma and Eli Lilly Japan disclosed a commercial alliance for tirzepatide in Japan in May 2024. Tirzepatide targets diabetes and obesity. This partnership was intended to improve treatment options in Japan, thereby reflecting the continued emphasis on developing innovative treatments to address the dual challenges of chronic diseases.

Japan Diabetes Drugs Market Statistics, By Region

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Kanto region, Kansai/Kinki region, Central/Chubu region, Kyushu-Okinawa region, Tohoku region, Chugoku region, Hokkaido region, and Shikoku region. These regions are emphasizing the use of personalized medicines.

Kanto Region Diabetes Drugs Market Trends:

In the Kanto region, especially in Tokyo, high levels of urbanization and rising obesity rates are uplifting the demand for diabetes drugs such as GLP-1 receptor agonists. Moreover, Yokohama is implementing these medications with a priority on dual-action treatments that target weight and diabetes control. Public-private collaborations in Kanagawa Prefecture promote awareness, thereby expanding access to advanced diabetes treatments.

Kansai/Kinki Region Diabetes Drugs Market Trends:

The Kansai/Kinki region has a surging demand for diabetes drugs driven by their benefits for the cardiovascular system, SGLT2 inhibitors are the focus of Kansai, which is headed by Osaka. Further supporting this trend, Kyoto University executes clinical trials on combination treatments for high-risk patients. Hyogo Prefecture emphasizes patient education campaigns, driving the adoption of advanced oral medications. With an aging demographic, Kansai’s healthcare providers prioritize therapies that balance efficacy and safety, integrating pharmaceuticals with lifestyle guidance for better diabetes management.

Central/Chubu Region Diabetes Drugs Market Trends:

In Chubu, Nagoya leads with increasing usage of long-acting insulin analogs, meeting the needs of older patients. Aichi Prefecture’s telemedicine expansion enables diabetes monitoring in rural areas, enhancing access to injectable therapies like GLP-1 analogs. The adoption of hybrid regimens combining oral drugs and insulin reflects the region’s focus on comprehensive care. These innovations cater to both urban and remote communities, strengthening treatment outcomes.

Kyushu-Okinawa Region Diabetes Drugs Market Trends:

The diabetes drug sector in the Kyushu-Okinawa region witnessed a growing demand for affordable generics, particularly in Fukuoka. Kagoshima enhances drug access through mobile health initiatives, ensuring continuity in remote areas. The region’s emphasis on affordability and outreach supports equitable healthcare while meeting diverse patient needs.

Tohoku Region Diabetes Drugs Market Trends:

Tohoku, with cities like Sendai, promotes early diagnosis and GLP-1 receptor agonists for weight and glucose control. Yamagata Prefecture integrates lifestyle interventions alongside medication, improving patient outcomes. Post-reform investments in healthcare facilities have boosted advanced drug availability, addressing the needs of the region’s aging population. Public awareness campaigns and improved access drive demand for innovative therapies, aiding prevention and complication management.

Chugoku Region Diabetes Drugs Market Trends:

Hiroshima leads Chugoku in adopting DPP-4 inhibitors, supported by regional diabetes education programs. Shimane’s rural areas benefit from enhanced drug distribution, thereby addressing gaps in advanced therapy access. Okayama’s healthcare institutions integrate oral medications with continuous glucose monitoring systems. Pharmaceutical collaborations expand availability, catering to an aging demographic seeking effective and user-friendly treatment options.

Hokkaido Region Diabetes Drugs Market Trends:

Hokkaido focuses on rapid-acting insulin due to extreme weather influencing blood glucose stability. Sapporo enhances drug adherence through education programs, while Asahikawa clinics prioritize personalized treatment plans. The region sees rising demand for injectables, addressing its high diabetes prevalence. Advances in insulin analog research align with efforts to improve accessibility and outcomes, particularly in communities with unique climate-related health challenges.

Shikoku Region Diabetes Drugs Market Trends:

Shikoku’s diabetes drug market emphasizes fixed-dose combinations for improved convenience, particularly in Matsuyama. Tokushima drives the adoption of GLP-1 analogs for individuals with obesity-linked diabetes. Regional hospitals partner with pharmaceutical companies to ensure equitable drug access in underserved areas. Public campaigns addressing prevention and early intervention strengthen demand for innovative treatments, reducing long-term complications across the region.

Top Companies Leading in the Japan Diabetes Drugs Industry

The report offers an in-depth evaluation of the competitive landscape in Japan's diabetes drugs market. It includes an analysis of market structure, positioning of leading players, key strategies driving success, a competitive dashboard, and a company evaluation quadrant. Moreover, the research offers a thorough analysis of profiles of well-known key market players, emphasizing their product portfolios, business plans, and recent advances. This comprehensive analysis aids in determining market trends, expansion prospects, and competition in Japan's diabetic drug market.

Japan Diabetes Drugs Market Segmentation Coverage

On the basis of the type, the market has been bifurcated into insulins [basal or long acting insulins (lantus (insulin glargine), levemir (insulin detemir), toujeo (insulin glargine), tresiba (insulin degludec), and basaglar (insulin glargine)), bolus or fast acting insulins (novorapid/novolog (insulin aspart), humalog (insulin lispro), and apidra (insulin glulisine)), traditional human insulins (novolin/actrapid/insulatard, humulin, insuman), biosimilar insulins (insulin glargine biosimilars and human insulin biosimilars)], oral anti-diabetic drugs, [biguanides (metformin), alpha-glucosidase inhibitors, dopamine d2 receptor agonist( bromocriptin), sglt-2 inhibitor (invokana (canagliflozin), jardiance (empagliflozin, farxiga/forxiga (dapagliflozin), suglat (ipragliflozin), dpp-4 inhibitors (onglyza (saxagliptin), tradjenta (linagliptin), vipidia/nesina (alogliptin), galvus (vildagliptin)), sulfonylureas, and meglitinides], non-insulin injectable drugs [glp-1 receptor agonists( victoza (liraglutide), byetta (exenatide), bydureon (exenatide), trulicity (dulaglutide), lyxumia (lixisenatide)), amylin analogue (symlin (pramlintide))], and combination drugs [insulin combinations (novomix (biphasic insulin aspart), ryzodeg (insulin degludec and insulin aspart), and xultophy (insulin degludec and liraglutide), and oral combination (janumet (sitagliptin and metformin))]. These options address diverse needs, offering tailored solutions for managing blood sugar levels, improving patient compliance, and minimizing complications associated with diabetes. They include a range of injectable and oral treatments that enhance glucose control, reduce insulin resistance, and provide combination therapies to optimize efficacy, catering to varying stages and types of diabetes management.
Based on the distribution channel, the market is categorized into online pharmacies, hospital pharmacies, and retail pharmacies. Various distribution channels provide accessible options for diabetes medications, ensuring patients receive timely treatments through convenient platforms, healthcare facilities, and localized outlets tailored to diverse needs and preferences.

Report Features	Details
Market Size in 2024	USD 4.4 Billion
Market Forecast in 2033	USD 5.9 Billion
Market Growth Rate 2025-2033	3.5%
Units	Billion USD
Scope of the Report	Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment: Type Distribution Channel Region
Types Covered	Insulins: Basal or Long Acting Insulins, Bolus or Fast Acting Insulins, Traditional Human Insulins, Biosimilar Insulins Oral Anti-Diabetic Drugs: Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitor, DPP-4 Inhibitors, Sulfonylureas, Meglitinides Non-Insulin Injectable Drugs: GLP-1 Receptor Agonists, Amylin Analogue Combination Drugs: Insulin Combinations, Oral Combination
Distribution Channels Covered	Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
Regions Covered	Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region
Customization Scope	10% Free Customization
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Browse IMARC Related Reports on Diabetes Drugs Market:

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Japan Diabetes Drugs Market Expected to Reach USD 5.9 Billion by 2033 - IMARC Group

Purchase Options New Year Sale

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.